Literature DB >> 20542475

Simultaneous determination of cytosine arabinoside, daunorubicin and etoposide in human plasma.

Mikkel Krogh-Madsen1, Steen Honoré Hansen, Per Hartvig Honoré.   

Abstract

A method for simultaneous bioanalysis of the three cytotoxic drugs cytosine arabinoside, daunorubicin and etoposide in human plasma was developed and validated. A HPLC method with ultra-violet and fluorescence detection, preceded by mixed-mode cation-exchange solid phase extraction sample preparation, was used for the quantification of the analytes. The assay was used for the simultaneous measurement of cytosine arabinoside, daunorubicin and etoposide with linearity in the ranges of 13-1500 ng/mL, 15-1000 ng/mL and 52.5-3500 ng/mL, respectively. The chromatographic run-time was 15.5 min. The overall precision (% relative standard deviation) was within 0.2-13.5% and the recovery ranged between 86.1% and 110.1% for the three drugs at all concentrations tested. Plasma samples were stable for at least two months when stored at -20 degrees C. The method was successfully applied to quantification of the three drugs in blood samples from patients undergoing induction treatment for acute myeloid leukaemia, thus demonstrating its suitability for clinical studies. 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20542475     DOI: 10.1016/j.jchromb.2010.05.031

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  2 in total

1.  Febrile neutropenia in chemotherapy treated small-cell lung cancer patients.

Authors:  Renata Rezonja Kukec; Iztok Grabnar; Tomaz Vovk; Ales Mrhar; Viljem Kovac; Tanja Cufer
Journal:  Radiol Oncol       Date:  2015-03-25       Impact factor: 2.991

Review 2.  Metabolomics as an Important Tool for Determining the Mechanisms of Human Skeletal Muscle Deconditioning.

Authors:  Isabelle Alldritt; Paul L Greenhaff; Daniel J Wilkinson
Journal:  Int J Mol Sci       Date:  2021-12-17       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.